Comparative study of the pharmacokinetic characteristics of slow release theophylline oral preparations in Thai children with persistent asthma

Asian Pacific Journal of Allergy and Immunology

Volumn 17, Issue 4, 1999, Pages 255-259

  Trakultivakorn, Muthita ^a   Kanthawatana, Sukanya ^a   Tontayapiwat, Arunee ^a   Jiraporncharoen, Kraungkan ^b  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; THEOPHYLLINE; UNCLASSIFIED DRUG;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; MALE; MEAN RESIDENCE TIME; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SLOW RELEASE FORMULATION; THAILAND; XANTHIUM;

ADMINISTRATION, ORAL; ADOLESCENT; AREA UNDER CURVE; ASTHMA; CHILD; CHRONIC DISEASE; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HALF-LIFE; HUMANS; MALE; SOFTWARE; THAILAND; THEOPHYLLINE;

EID: 0032693341     PISSN: 0125877X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Barnes PJ, Pauwels RA. Theophylline in the management of asthma: time for reappraisal? Eur Respir J 1994; 7: 579-91.
2. Finnerty JP, Lee C, Wilson S, Madden J, Djukanovic R, Holgate ST. Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: a placebo-controlled parallel group study. Eur Respir J 1996; 9: 1672-7.
3. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma. Demonstration of withdrawal therapy. Am J Respir Crit Care Med 1995; 151: 1907-14.
4. Mascali JJ, Cvietusa P, Negri J, Borish L. Anti-inflammatory effects of theophylline; modulation of cytokine production. Ann Allergy Asthma Immunol 1996; 77: 34-8.
5. Okubo Y, Hossain M, Horie S, et al. Inhibitory effects of theophylline and procaterol on eosinophil function. Intern Med 1997; 36: 276-82.
6. Crocker IC, Townley RG, Khan MM. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. Immunopharmacol 1996; 31: 223-35.
7. Littenberg B. Aminophylline treatment in severe, acute asthma. JAMA 1988; 259: 1678-84.
8. Needleman JP, Kaifer MC, Nold JT, et al. Theophylline does not shorten hospital stay for children admitted for asthma. Arch Pediatr Adolesc Med 1995; 149: 206-9.
9. National Heart, Lung and Blood Institute. Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. Bethesda, Maryland, National Institute of Health Publication No. 97-4051A. 1997.
10. National Heart, Lung, and Blood Institute. Asthma management and prevention: a practical guide for public health officials and health care professionals. Bethesda, Maryland, National Institute of Health Publication No. 96-3659A. 1995.
11. Thoracic Society of Thailand, Allergy and Immunology Society of Thailand and Asthma Club of Thailand. Guidelines for management of asthma in Thailand.Bangkok: O.S. Printing House, 1994.
12. Baker JR, Moessner H, Gonzalez U, et al. Clinical relevance of the substitution of different brands of sustained-release theophylline. J Allergy Clin Immunol 1988; 81: 664-5.
13. Hendeles L, Iafrate RP, Weinberger M. A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products. Clin Pharmacokinet 1984; 9: 95-135.
14. Zaske DE, Miller KW, Strem EL, et al. Oral aminophylline therapy: increased dosage requirement in children. JAMA 1977; 237: 1453-5.
15. Vichyanond P, Aranyanark N, Visitsuntorn N, Tuchinda M. Theophylline pharmacokinetics in Thai children. Asian Pac J Allergy Immunol 1994; 12: 137-43.
16. Weinberger M. Clinical and pharmacokinetic concerns of 24-hour dosing with theophylline. Ann Allergy 1986; 56: 2-8.
17. Kanthawatana S, Tontayapiwat A, Tonsuwannont V, and Manorot M. A single-dose comparison of three slow release theophylline oral preparations in healthy Thai volunteers. Asian Pac J Allergy Immunol 1996; 14: 13-8.
18. Tuchinda M, Habanananda S, Srimaruta N, Chaichanwatanakul K, Geadsomnuig S. Sustained-release theophyl-line therapy in Thai asthmatic children, J Med Ass Thailand 1985; 68: 81-6.
19. Menendez R, Kelly W, Howick J, et al. Sustained-release theophylline: Pharmacokinetic and therapeutic comparison of two preparations. AJDC 1983; 137: 469-72.
20. Weinberger M, Hendeles L, Wong L. Relationship of formulation and dosing interval to fluctuation of serum theophylline concentration in children with chronic asthma. J Pediatr 1981; 99: 145-52.
21. Kelly HW, Murphy S. Efficacy of a 12-hour sustained-release preparation in maintaining therapeutic serum theophylline levels in asthmatic children. Pediatrics 1980; 66: 97-102.
22. Rachelefsky G, Rohr A, Katz R, et al. Sustained-release theophylline preparations in asthmatic children. AJDC 1986; 140: 336-40.